Clinical Trials Logo

Filter by:
NCT ID: NCT04924686 Recruiting - Colorectal Cancer Clinical Trials

Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases

Start date: May 10, 2020
Phase:
Study type: Observational

Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).

NCT ID: NCT04924647 Recruiting - Clinical trials for Rosai-Dorfman Disease

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Start date: June 8, 2021
Phase: Phase 2
Study type: Interventional

Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect in recurrent/refractory skin RDD. The investigators want to analyze the efficacy and toxicity of lenalidomide combined with dexamethasone regimens in the treatment of RDD among adult patients at our hospital.

NCT ID: NCT04924621 Recruiting - Airway Control Clinical Trials

Sedation Compaired With Anesthesia With THRIVE in Endotracheal Intubation With Difficult Airways

Start date: June 10, 2021
Phase: N/A
Study type: Interventional

To compare the difference in endotracheal intubation in participants with difficult airway between under general anesthesia by Transnasal Humidified Rapid-Insufflation Ventilatory Exchange and under traditional sedation by mask ventilation. The investigators focus on the different outcomes in oxygenation maintaince, carbon dioxide removal and the effectiveness of safety apnea time, to evaluate the safety of receiving endotracheal intubation under general anesthesia in participants with difficult airway.

NCT ID: NCT04924361 Recruiting - Dementia Clinical Trials

Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

Start date: December 1, 2020
Phase:
Study type: Observational

Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.

NCT ID: NCT04924309 Recruiting - Infertility, Male Clinical Trials

Stress in Couples Undergoing Assisted Reproduction Technology With Donor Sperm and Its Impact on Pregnancy Outcomes

Start date: July 5, 2021
Phase:
Study type: Observational [Patient Registry]

Donor sperm provides a viable option for patients with significant male factor infertility. However, since the source of sperm is not from the male partner, the psychological burden of these couples is more pronounced and complex than other patients.The purpose of this study is to investigate the stress faced by participants undergoing assisted reproduction with donor sperm and to further investigate its impact on pregnancy outcomes.

NCT ID: NCT04924192 Recruiting - Clinical trials for Advanced Lung Carcinoma

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.

NCT ID: NCT04924075 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Start date: August 12, 2021
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

NCT ID: NCT04923945 Recruiting - Clinical trials for Non-small Cell Lung Cancer Metastatic

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Start date: August 19, 2021
Phase: Phase 3
Study type: Interventional

Treating Non-small Cell Lung Cancer (NSCLC) Patients with MET exon 14mutations with Savolitinib

NCT ID: NCT04923932 Recruiting - Gastric Cancer Clinical Trials

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Start date: July 27, 2021
Phase: Phase 2
Study type: Interventional

Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib

NCT ID: NCT04923919 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Start date: September 14, 2021
Phase: Early Phase 1
Study type: Interventional

Researchers plan to enroll a total of 100 patients with relapsed, refractory acute myeloid leukemia (AML) to receive a single dose of autologous CAR T cells.The safety of CAR T therapy was evaluated by observing adverse events after cell therapy;The efficacy of CAR-T therapy was evaluated against the outcome of patients' own past standard treatment regimens or historical data.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the pharmacokinetics (PK) of CAR T cells.